HighTide Capital and Portfolio Companies Honored at the 9th Healthcare Investment Excellence Awards, Winning 'Best Healthcare Investment Return Fund of the Year'

Jul 30, 2025 11:25 CST Updated 11:25

TowardPi

High-end Ophthalmic Medical Device Developer

DK Medtech

Vascular Interventional Balloon Product Developer

Kanova Biopharma

Innovative Immunotherapy Antibody Drug Developer

▲ The 15th issue of GaoTJ Insights, GaoTJ's industry research journal, is about to be released. The core research report focuses on AI in healthcare, providing an in-depth analysis of how AI technology is driving medical research and clinical applications towards a new paradigm. Multiple members of the GaoTJ ecosystem have been invited to discuss their experiences, innovations, and practices in AI healthcare. Stay tuned.

On July 30, Haoyue Capital officially released the "9th Healthcare Investment Excellence Awards." As an important barometer for assessing corporate market value and institutional brand influence in the healthcare investment industry, the Healthcare Investment Excellence Awards consistently uphold the principles of fairness, impartiality, objectivity, and neutrality. Each year, awards are granted to outstanding investment institutions and healthcare enterprises that have made remarkable contributions. Gao Tejia Investment and several ecosystem members were honored with awards at this year’s Healthcare Investment Excellence Awards.‍‍‍

·Annual Healthcare Best Return on Investment Fund·

Gortec Investment

·Best Company for Annual Innovative Medical Devices·

TowardPi

DK Medtech

·Best Innovative Pharmaceutical Company of the Year·

Kanova Biopharma

In June 2024, TowardPi Medical announced the completion of its D-round financing worth 200 million RMB, with participation from Gao Tejia. In March 2025, TowardPi Medical again announced the completion of a total financing scale of 500 million RMB.RMB E-round financing.TowardPi was founded in 2017, with its core technology originating from the transformation of scientific achievements at Tsinghua University. The core technical team, composed of dozens of Tsinghua faculty, students, and alumni, has rapidly achieved breakthroughs in multiple categories of high-end ophthalmic equipment through the vertical integration of clinical ophthalmology needs, innovative system functions, and high-performance upstream components.As a leading Chinese ophthalmic enterprise hailed by the internationally renowned research institution Frost & Sullivan as "a representative brand of China-produced comprehensive ophthalmic diagnostic and treatment equipment," TowardPi Medical is set to make a push to become the "first stock" in ophthalmic medical devices on the STAR Market.

In December 2021, DK Medtech announced the completion of a financing round worth hundreds of millions of RMB, with participation from GaoTJia Investment. Founded in 2015, DK Medtech has become a leading company in China.Leading Full-RangeDK Medtech, an innovative enterprise in interventional balloons, has developed more than ten types of balloons, including standard balloons, high-pressure balloons, scoring balloons, and drug-coated scoring balloons. Its product line covers the needs of almost all vascular intervention fields, such as cardiovascular intervention, peripheral intervention, and neurointervention. Multiple products have obtained international certifications such as EU CE MDR and US FDA. Its self-developed directional scoring technology is applied in coronary scoring balloons, peripheral scoring balloons, and drug-coated scoring balloons. According to the published pre-market RCT studies, its clinical performance shows significantly better clinical benefits compared to imported control groups, achieving excellent results and market position in niche markets.

In July 2023, Kanova BiopharmaAnnounced the completion of over 100 million RMB in financing, led by GaoTJ Investment.Kanova Biopharma was founded in 2015 by renowned international immunologist Academician Chen Dong. The company is committed to developing innovative biologics for autoimmune diseases and immuno-oncology based on cutting-edge immunological research worldwide. It focuses on creating novel therapies with proprietary intellectual property rights originating from China and targeting the global market, aiming to provide patients with first-in-class or best-in-class treatment options. In July 2025, Kanova Biopharma announced that XKH004, the first domestically developed IL-17A/F monoclonal antibody in China, had successfully reached the primary endpoints in Phase III clinical trials for psoriasis and ankylosing spondylitis, offering the potential for improved therapeutic options for patients.

About Gortec Investment

Gao Tejia Investment was established in Shenzhen in 2001, being the first in the industry to propose the investment model of "thematic industry investment." It focuses on investment in the healthcare industry, primarily through strategic equity investments, covering all investment stages including VC, PE, Pre-IPO, and mergers and acquisitions. It has one of the few professional investment teams in China that deeply focuses on the healthcare track, building an investment ecosystem platform for the healthcare industry, and is committed to becoming a healthcare investment institution with global influence.

Gortega Investment's asset management scale exceeds 23 billion RMB, with 35 healthcare industry funds. It has invested in over 110 healthcare companies and facilitated the successful listing of 38 enterprises, including Mindray Medical, United Imaging Healthcare, and Akeso Biopharma. Gortega's investment business is rooted in China while targeting the global market. Operating centers have been established in Shenzhen, Shanghai, Beijing, Hong Kong, and other locations. The firm is committed to investing in outstanding healthcare companies worldwide, creating new development opportunities for global capital and medical enterprises, and assisting entrepreneurs in building great companies.